← Back to Clinical Trials
Recruiting NCT04668560

NCT04668560 Effects of the 5 Ways to Wellbeing Course Effects of the 5 Ways to Wellbeing Course

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04668560
Status Recruiting
Phase
Sponsor Norwegian Institute of Public Health
Condition Wellbeing
Study Type INTERVENTIONAL
Enrollment 700 participants
Start Date 2020-02-01
Primary Completion 2025-06-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Five ways to wellbeing course

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 700 participants in total. It began in 2020-02-01 with a primary completion date of 2025-06-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Norway and other Western industrialized countries are facing major challenges in terms of preventable health problems, high work absence, largescale demographic changes and rising social inequalities in health. This project addresses the need for effective means to meet these important challenges. The project will scientifically evaluate The 5 Ways to Wellbeing course (5Ways), a novel measure aiming to promote wellbeing and integration, health and work adherence. Subjective wellbeing is systematically and prospectively related to important individual and societal outcomes, including social connectedness and integration, innovation, productivity, work performance, healthy behaviours, health and longevity. Promotion of wellbeing may therefore contribute to address the urgent societal ailments of today. Intervention effects and cost effectiveness of the 5Ways will be examined in-depth in four real-life settings, using quantitative methods. Specifically, we will investigate course impact wellbeing, health and work adherence among users of The Norwegian Labour and Welfare Administration (NAV) and clients in Healthy Life Centres. If effective, the course may be implemented nationwide and contribute to increase wellbeing and work participation. Findings from the study may thus contribute to enable municipalities and workplaces to make better priorities for promoting work presence, reducing suffering and improving mastery and quality of life among their inhabitants.

Eligibility Criteria

Inclusion Criteria: * individuals with, or at high risk of disease, who need support in health behaviour change and in coping with health problems and chronic disease. * individuals on sick leave, work assessment allowance (AAP) and disability pension Exclusion Criteria: * Severe mental illhealth * impaired cognitive functioning

Contact & Investigator

Central Contact

Maja ME Eilertsen, MD

✉ maja.eilertsen@fhi.no

📞 +47 95895434

Principal Investigator

Anne Reneflot, PhD

STUDY CHAIR

Department Director

Frequently Asked Questions

Who can join the NCT04668560 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Wellbeing. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04668560 currently recruiting?

Yes, NCT04668560 is actively recruiting participants. Contact the research team at maja.eilertsen@fhi.no for enrollment information.

Where is the NCT04668560 trial being conducted?

This trial is being conducted at Oslo, Norway.

Who is sponsoring the NCT04668560 clinical trial?

NCT04668560 is sponsored by Norwegian Institute of Public Health. The principal investigator is Anne Reneflot, PhD at Department Director. The trial plans to enroll 700 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology